Prognosis
Breaking Into Breast Cancer, Immune Therapy Shows Wider Promise
- Roche, Bristol data suggest patient selection as way forward
- Beyond hype, latest ESMO results show ‘a lot of substance’
Photographer: Steve Gschmeissner/Science Photo Library RM
This article is for subscribers only.
Drugmakers are honing in on which cancer patients will benefit from new immune therapies -- and finding many more than skeptics had thought.
For the first time, a clinical trial showed that a treatment with one of the new generation of drugs designed to unleash the body’s own immune system against tumors can help some women with the most aggressive type of breast cancer live longer. The study was unveiled by Roche Holding AG at Europe’s biggest cancer conference.